Prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes: 2018 clinical practice guideline

Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in Chronic Kidney Disease (CKD) is an extensive update of the prior (2008) hepatitis C virus (HCV) and CKD KDIGO guideline. This update reflects the major advances since the introduction of direct acting antiviral (DAA) agents in the management of HCV in the CKD population. Methods: The KDIGO HCV and CKD Guideline Development Work Group defined the scope of the Guideline, gathered evidence, determined topics for systematic review, and graded the quality of evidence previously summarized by an Evidence Review Team. Appraisal of the quality of the evidence and rating the strength of the recommendations followed the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Searches of the English language literature were conducted through May 2017 and were supplemented with targeted searches for studies of DAA treatment and with abstracts from Nephrology, Hepatology and Transplantation conferences. A public review process involving numerous stakeholders, subject matter experts, and industry and national organizations informed final modification of the guideline. Recommendations: The updated guideline included 66 recommendations. This synopsis focus is on 38 key recommendations pertinent to prevention, diagnosis, treatment and management of HCV in adult CKD populations